Annovis Bio
@AnnovisBio
Followers
676
Following
208
Media
195
Statuses
264
Clinical-stage drug platform company addressing neurodegenerative diseases like Alzheimer's and Parkinson's through improvement of axonal transport
Malvern, PA
Joined October 2021
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
James Earl Jones
• 697064 Tweets
Haitians
• 390659 Tweets
iPhone16
• 207879 Tweets
Tyreek
• 166894 Tweets
Cops
• 158487 Tweets
Darth Vader
• 146150 Tweets
SIEMPRE FURIA SCAGLIONE
• 129541 Tweets
Jets
• 114504 Tweets
#WWERaw
• 102559 Tweets
49ers
• 89557 Tweets
Yunes
• 71782 Tweets
ZEE PRUK BIRTHDAY
• 61026 Tweets
シーザリオ
• 45173 Tweets
#MartinFierro
• 38562 Tweets
Aaron Rodgers
• 33735 Tweets
ガチャチケット
• 18085 Tweets
#NYJvsSF
• 17521 Tweets
Purdy
• 17141 Tweets
Jordan Mason
• 16800 Tweets
#FTTB
• 16574 Tweets
性の対象
• 16379 Tweets
Deebo
• 15274 Tweets
Saleh
• 15187 Tweets
Niners
• 14296 Tweets
Gunther
• 13992 Tweets
キスィズ
• 12577 Tweets
Aiyuk
• 12501 Tweets
We have been talking about the potential of
#buntanetap
to treat more than
#Alzheimers
disease. Today our CEO Dr. Maria L. Maccecchini takes the opportunity to explain how one drug can be so broadly applicable. $ANVS
🧵Thread below.
5
1
34
We’re thrilled to share that the FDA has approved our transition to a new solid form of
#buntanetap
for our clinical trials targeting
#Alzheimers
and
#Parkinsons
diseases! $ANVS
Read more:
5
1
35
Great to see such an inspiring story from a patient who participated in our Phase 3 PD trial.
Written after watching the Annovis webinar on the Parkinson’s Trial results:
I participated in the trial at the Ohio State University from January 2023 through July 2023. During the six months I was taking buntanetap, I saw significant improvement in my symptoms.
Let me
6
4
34
4
2
34
$ANVS announces new data from the Phase III study of
#buntanetap
in
#ParkinsonsDisease
. The company will host a live webcast today at 4:30pm ET to discuss the study's results. The presentation will be followed by a Q&A.
Full release:
2
9
31
We are happy to announce that the data cleaning for our phase II/III study of
#buntanetap
in
#Alzheimers
is now completed.
Topline efficacy data is expected in April. $ANVS
Full release at
5
5
31
How does
#buntanetap
work?
It targets the iron regulatory protein 1 and keeps mRNA bound, inhibiting the translation of neurotoxic proteins (i.e. APP).
Our latest publication provides further support for
#buntanetap
's role as APP inhibitor in humans.
4
1
29
We are thrilled to announce the completion of our phase III study of
#ParkinsonsDisease
. $ANVS
The data readout is expected in January 2024.
Learn more at
0
3
29
$ANVS announced unblinding for the Phase III data from Parkinson's study and shares the topline data is now expected in June.
#buntanetap
Read more for details ->
2
4
28
How exactly does
#buntanetap
work in
#Parkinsons
brain?
Buntanetap inhibits the production of alpha-synuclein and other neurotoxic proteins which are major players in driving
#neurodegeneration
.
Learn more about our science at
0
4
25
Buntanetap is found safe and effective in carriers of
#APOE4
, a recently recognized genetic cause of
#Alzheimers
. These findings position
#buntanetap
superior to current anti-amyloids that are associated with increased ARIA risks in APOE4 homozygotes.
🔗
2
5
23
Save the date! Next week, July 31, $ANVS will present Phase 2/3 data from the recently completed
#Alzheimers
study at the
#AAIC24
(
@alzassociation
).
More about the conference:
0
1
25
On July 2nd, the US President signed a bill aimed at tackling
#Parkinson
's into law, which covers government-wide support to address the disease by forming a Parkinson's advisory committee to help coordinate federal efforts toward the united goal.
3
4
22
Having a fantastic time in Lisbon at
#ADPD2024
! Our CEO, Maria Maccecchini participated in an insightful discussion on synucleinopathies. Engaging conversations and new connections all around.
7
1
23
$ANVS invites you to an investor webcast on July 2, 2024, at 4:30pm ET.
We'll discuss recent
#buntanetap
advancements from Phase III
#Parkinsons
study and our future plans.
Register now to join us:
#Biotech
#Alzheimers
#Parkinsons
3
5
22
$ANVS will present at the upcoming AD/PD 2023 Conference (
@adpdnet
) on March 28-April 1 in Gothenburg, Sweden. The presentations will include interim analysis of PD clinical data and more.
For information, follow the link:
1
4
22
$ANVS announced last patient last visit for its phase II/III trial of
#buntanetap
in
#Alzheimers
Disease.
In total, 327 patients completed the study.
Learn more at
2
1
22
All boxes checked...Teeing Up A Clinical Catalyst: Ready to start recruitment of Ph3 evaluating Buntanetap vs placebo in 450 early
#Parkinsons
disease patients. Final protocol & GMP material - accepted. 1-month restriction on treatment duration - removed. Longer studies - enabled
4
2
22
$ANVS announces the filing of a patent covering new solid forms of
#buntanetap
with improved properties.
Learn more at
#Biotech
#Alzheimers
#Parkinsons
#Innovation
1
6
21
$ANVS announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months.
Read the full news release:
1
3
21
$ANVS announces the addition of four new professionals expanding its executive team.
More details at:
8
1
19
$ANVS is attending the AD/PD 2024 conference in Lisbon, March 5-9.
Our CEO, Maria Maccecchini, PhD, will participate in a forum discussion along with other industry leaders.
#ADPD2024
For more details, click the link ->
5
1
18
We are pleased to announce that our lead candidate
#buntanetap
advances to Phase 2/3 clinical trial for moderate
#AlzheimersDisease
. $ANVS
Click the link to see the press release
2
4
18
$ANVS shares patient enrollment update for Phase 3 study of
#buntanetap
for the treatment of
#parkinsonsdisease
.
Read more at ->
0
2
18
$ANVS will present findings from its recent Phase 2/3 Alzheimer's study at
#AAIC2024
, July 28-August 1.
Find details at:
1
3
17
$ANVS announces new preclinical data showing strong synergistic effect of
#buntanetap
and
#GLP1
agonist Trulicity® on enhancing cognition.
Find more details at:
1
3
18
$ANVS today announced corporate updates and financial results for 1Q 2024.
For more information, see release at
1
1
17
Meet Cheng Fang, Ph.D., our SVP of Research and Development, who is at the forefront of designing and implementing our clinical trials, both for
#Alzheimers
and
#Parkinsons
diseases.
Learn about Dr. Fang’s work and expertise in the profile below.
1
1
19
In a recent article from
@TrialsArena
by
@WillNewton19
, CEO and founder of Annovis, Maria Maccecchini, explained the recent successful Ph. 2
#clinicaltrials
completed for
#ANVS401
and how
#COVID19
impacted clinical trial recruitment. $ANVS
Read more:
0
2
13
Breaking news!
$ANVS announced significant data from its Phase II/III study -
#buntanetap
shows dose-dependent improvement in patients with early
#AlzheimersDisease
.
Full release ->
5
2
17
Part Deux – Summer Radar Alert Plus A Conviction Recharge: We will pursue a Ph3 in
#Alzheimers
; steps underway; see Ph2 data again. AD & PD clinical programs in focus while strategically considering/advancing $ANVS Buntanetap for several distinct neurological conditions/disorders
1
3
17
Annovis is now enrolling individuals with
#AlzheimersDisease
for Phase 2/3 clinical trial. For more information or to participate, contact us
$ANVS
1
3
16
$ANVS announces corporate updates and financial results for 4Q and full year 2023.
Full release at ->
1
0
15
We are thrilled to announce the expansion of our IP portfolio by securing a new patent covering the use of
#buntanetap
for the treatment of acute traumatic brain injury. $ANVS
Find more details at:
0
0
17
Annovis is now enrolling individuals with
#ParkinsonsDisease
for Phase 3 clinical trial. For more information or to participate, contact us
$ANVS
1
1
17
Did you miss yesterday's webcast? Catch up on the most recent Parkinson's Phase III study update followed by a Q&A session from our CEO, Maria Maccecchini, PhD, by visiting our YouTube channel
#Parkinsons
#ParkinsonsDisease
#Biotech
#ClinicalTrials
1
4
16
Join us in congratulating Melissa Gaines on her promotion to Senior VP, Clinical Operations!
2
1
16
As summer winds down, we’re reflecting on the milestones we've achieved over the past months. Our team has been hard at work, setting the stage for an impactful Fall. With an FDA meeting ahead, we’re already preparing for Phase 3 AD study, ensuring we can start without delay.
3
0
17
$ANVS presented three posters at the
#AAIC23
in Amsterdam, Netherlands.
Read the full news release:
#Alzheimers
#Parkinsons
0
0
16
We are honored to have been recognized at the 2023 Inno Fire Awards. We are proud of our work in developing transformative therapies for neurodegenerative disorders. Thanks to the
@PHLBizJournal
for the incredible event. Let’s keep the fire of innovation burning bright!
0
2
16
#DYK
: Alzheimer's disease is the most common form of dementia, accounting for approximately 60-70% of cases? Let's spread awareness about this disease, support research, and promote early detection to improve the lives of those affected.
#AlzheimersAwareness
0
0
15
"This company is running a trial on one of the only drugs that could actually modify or reduce Parkinson’s disease, rather than just alleviating symptoms.” Thank you John Blankenhorn for recognizing our work.
@InvestorPlace
0
3
16
Not one, but multiple neurotoxic proteins contribute to the onset of
#Parkinson
’s and
#Alzheimer
’s. Other companies tackle only one protein. We address multiple. $ANVS
#Buntanetap
#neurotoxic
#brain
0
2
16
#DYK
:
#ParkinsonsDisease
affects more than 10 million people across the globe? This neurodegenerative disorder can cause tremors, stiffness, and impaired movement. Let's raise awareness, support research for better treatments, and provide care to enhance quality of life.
0
0
15
In addition to
#buntanetap
, $ANVS is also developing drug candidate ANVS301 for advanced
#AD
. Learn more about our pipeline:
#alzheimers
#dementia
#neurodegeneration
2
2
15
As JP Morgan Healthcare Conference is underway, $ANVS is getting ready to connect with global industry leaders.
See you there!
#JPMorgan2023
#JPM2023
2
0
14
2022 kick-off! Annovis Bio announced today that Dr. Maria Maccecchini, CEO, will present at 2 upcoming conferences:
#HCWBioConnect
and
#BiotechShowcase
. $ANVS
#JoinUs
during the conference and find more details here:
@demycolton
@HCWCO
0
3
14
Last month, the Senate passed the National Plan to End Parkinson’s Act! This no-cost legislation unites experts to advance prevention, treatment, and a cure for
#Parkinsons
. As our Phase 3 data is on the way, we’re thrilled for this milestone!
0
3
14
Today we announced the expansion of our
#buntanetap
patent portfolio with granted US patents US11400075, US11376238, & US11382893. The patents cover methods of treating Amyloid Lateral Sclerosis, Huntington’s disease, & prion disease. $ANVS
Learn more at
1
1
14
$ANVS just announced approval for EU clinical trial sites for Phase 3 study in
#Parkinsons
.
Read full announcement:
0
3
15
Meet Melissa Gaines, our powerhouse SVP of Clinical Operations. Thanks to her expertise, we exceeded patient enrollment targets in our latest AD and PD trials. A true leader in driving clinical progress!
2
2
14
#Update
! Annovis Bio announced positive feedback from the
@FDA
earlier today, with clear guidance on initiation of two Phase 3
#clinicaltrials
for early and late
#PD
through dosing with
#Buntanetap
.
Read more:
1
5
15
Summer Radar Alert Plus A Conviction Recharge: We expect to start recruitment for our Ph3 evaluating Buntanetap versus placebo in 450 early Parkinson’s disease patients. Worth looking back at data from our Ph2 in early and moderate Parkinson’s disease patients. $ANVS
#Parkinsons
1
2
15
We are excited to share that we have reached the halfway mark in our goal for patient enrollment in our phase II/III study of buntanetap. Currently, the study has enrolled 166 patients, and we are continuing to make remarkable progress in recruiting additional participants.
1
1
14
#WorldParkinsonsDay
"Annovis supports our community’s common efforts to foster innovation that will produce the greatest benefit to
#PD
patients. Our team remains committed to transforming their lives as we advance
#Buntanetap
in Ph3" Dr. Maccecchini $ANVS
0
1
15
#Buntanetap
, our therapy for
#Parkinson
’s and
#Alzheimer
’s is safe in humans at therapeutic doses. We are laser-focused on bringing this transformative therapy forward to patients.
2
2
15
Team Annovis would like to wish everyone Happy Holidays!
$ANVS
1
2
13
Great coverage by
@adnewstoday
of our recent results from the Phase 2/3
#Alzheimers
study demonstrating
#buntanetap
’s potential to improve cognition in patients with mild
#AD
.
1
2
14
#Buntanetap
is a translational inhibitor of APP!
Further look at earlier Phase 1b study by ADCS unveils confirmatory data in a new publication.
#AD
#Alzheimers
Check out the summary here
0
1
14
1
0
14
#Uplisting
#alert
! $ANVS will begin trading on
@NYSE
starting Nov. 18 after being approved to switch from
#NYSEAmerican
.
Read more:
0
5
14
Today we announced our second quarter financial results & recent highlights. We have made encouraging progress in advancing buntanetap for the treatment of
#Parkinsons
disease and a variety of other neurological injuries. More here:
0
1
14
In honor of
#NationalFamilyCaregiversMonth
, Annovis expresses gratitude to everyone who dedicates their time and energy to support family members suffering from serious diseases.
$ANVS
0
1
13
Annovis is restoring balance of key proteins to treat
#Parkinson
’s and
#Alzheimer
’s. Want to know more? Listen to Dr. Maria Maccecchini speak with Dr. Moira Gunn, host of the
#TechNation
podcast!
$ANVS
@biotechnation
0
2
14
We are very excited to be presenting updates on our upcoming Phase 3 trails evaluating
#Buntanetap
in
#PD
at the AD/PD International conference in Barcelona on Sunday, March 20.
For more details, make sure to check here: $ANVS
@adpdnet
0
2
14
Last week, $ANVS presented at ThinkEquity Conference 2022. In case you missed it, follow the link and watch the recording online ->
#ICYMI
0
1
14
Congratulations to our Founder and CEO Dr. Maria Maccecchini!
Our Women of Influence program celebrates the impactful businesswomen shaping Greater Philadelphia. Here's the first group of 2023 honorees.
0
0
1
0
1
14
Neurodegenerative diseases are one of the biggest unmet needs worldwide. Our Founder, President, and CEO, Dr. Maccecchini, spoke with
@mydocwire
about how
#buntanetap
is addressing this challenge by improving of nerve cell health -> $ANVS
1
2
14
In our recent
#Phase2
clinical trial, treatment with
#buntanetap
resulted in reduction of aggregating proteins and statistically significant improvement in motor function in
#Parkinsons
disease patients and cognition in
#Alzheimers
disease patients.
1
0
14
On June 11, $ANVS hosted a webinar to discuss recent Phase II/III
#Alzheimers
data and share an update on
#buntanetap
's safety and efficacy in
#APOE4
patients. The presentation was followed by a Q&A session.
Full recording can be found at
2
1
13
Our CEO, Maria Maccecchini, reviews Annovis accomplishments over 2021 and provides 2022’s insights in a new Shareholder Letter. $ANVS
Read more about our year in review and our resolutions for the new year:
0
3
14
Listen to the recent episode of Heroes of Healthcare Podcast (
@hofhpodcast
) where Maria Maccecchini, CEO of $ANVS, delves into the nature of
#dementia
and what the company is doing to prevent nerve cells from dying.
Click to listen ->
0
2
14
Check out a new episode of
@SliceofHC
podcast where Dr. Maria Maccecchini, President & CEO of $ANVS, talks about the challenges of working in neurodegenerative space and shares the company’s updates.
Listen here:
2
2
13
In light of a recent Chris Hemsworth’s revelation on
#Alzheimers
predisposition, Maria Maccecchini, CEO of $ANVS, highlights the importance of strong voices to improve awareness and understanding of the disease.
Full article at
@LongevityTech
->
0
2
14
FDA approval benefits patients, families & researchers. Patients will seek treatment sooner, & clinical trials will be completed earlier. We are encouraged that our treatment (one daily pill) is easier to administer, well-tolerated & shows no side effects.
0
1
14
How well do you know
#ParkinsonsDisease
?
It is the 2nd most common neurodegenerative disease after Alzheimer's, and the total economic burden exceeds $52 billion worldwide.
There is a dire need for novel therapies.
Learn about our work at
0
6
13
On
#WorldParkinsonsDay
, we are standing with people diagnosed with
#PD
and everyone who helps fight it. $ANVS is proud to be part of this fight by continuing to advance its drug candidate
#buntanetap
, which is currently in Phase 3 clinical study.
Visit us:
0
3
13
We highlighted significant restoration of
#cognition
and
#motorfunction
in
#AD
and
#PD
mice models, with biomarkers showing anticipated decline, in preclinical analyses of
#ANVS401
. $ANVS 🧵
1/
1
3
13
#ICYMI
, catch up on the latest article by TheIncMedia that dwells into the history of Annovis Bio and the person behind the company’s success, Maria Maccecchini, Founder and CEO of $ANVS.
Click the link to read ->
0
1
13
Next Tuesday, June 11, $ANVS is hosting a webcast to discuss recent company developments and future plans for
#buntanetap
.
Register today via the link ->
More details can be found at
0
0
13
Dr. Cheng Fang, SVP, R&D of $ANVS, will host a roundtable discussion on novel targets in
#Alzheimer
’s therapy at US East Coast
#CNS
Therapeutics Xchange (
@hub_xchange
) in Boston, on May 24 at 3pm EDT.
More details at
0
0
13
We are pleased to share our CEO, Maria Maccecchini's interview on Money Matters TV. Learn about Annovis Bio's advancements in Alzheimer's and Parkinson's treatments. $ANVS
Watch here:
#AnnovisBio
#Alzheimers
#Parkinsons
#Biotech
0
2
12
Today we announced third-quarter financial results and corporate updates. Full release available
#earnings
$ANVS
1
0
13
Don’t miss your chance to see Maria Maccecchini, CEO of $ANVS, as she presents at the Ladenburg Thalmann Healthcare Conference 2022.
Follow the link
0
2
13
This
#WorldParkinsonsDay
, Annovis joins
@ParkinsonsSpark
to encourage
#Parkinsons
community to share your Spark!
Spark is a new global symbol for
#PD
awareness.
Visit to learn how advocates unite globally to raise awareness.
0
0
13
Dr. Maria Maccecchini, Founder & CEO of $ANVS is among the finalists for the
@EYnews
Entrepreneur Of The Year® 2022 Greater
#Philadelphia
Award. Entrepreneur Regional award winners will be announced on June 23.
0
3
13
#WeAreHiring
– Annovis opens three positions to expand its growing team!
Apply on LinkedIn ->
0
1
13
Our lead candidate
#buntanetap
inhibits the translation of multiple neurotoxic proteins offering the therapeutic potential for different indications including
#AD
,
#PD
,
#FTD
, and
#CTE
.
More at
0
0
13
We look forward to unlocking the full potential of
#buntanetap
and addressing unmet needs across a range of acute and chronic neurological conditions.
See full release here:
0
1
13
On the day with the most light of the year, June 21, people from all over the world partake in fundraising initiatives to fight the darkness of
#AlzheimersDisease
.
Join the fight ->
@alzassociation
#TheLongestDay
#ENDALZ
0
3
12
$ANVS is proud to announce a new partnership with the
@CPathInstitute
as member of the Critical Path for Parkinson's Consortium. Annovis joins this consortium as one of many members advancing promising new therapies for
#ParkinsonsDisease
.
Learn more:
0
1
13
Dr. Cheng Fang,
#Annovis
VP of Research, will be presenting a poster highlighting the detailed mechanism of action for
#ANVS401
during
#CTAD21
.
#StayTuned
$ANVS
Read more:
0
4
13
Check our freshly published Phase 2a clinical data in
@jpreventionalz1
showing safety, tolerability, and efficacy of
#buntanetap
in
#Alzheimers
and
#Parkinsons
. $ANVS
Read the article here:
0
2
13
$ANVS is happy to share its participation at the upcoming
@longwoodleaders
WebConference on Jan. 6. Our CEO, Maria Maccecchini, will be joined by top R&D leaders to discuss Pipeline Optimization.
Click to register ->
#longwoodhealthcareleader
#pipeline
2
3
12
#MeetTheTeam
- We are happy to welcome Dr. Michal Christie to our team where he will take a role of a Vice President of Process Chemistry. $ANVS
0
1
12
Annovis team would like to express their gratitude and appreciation to all
#caregivers
. Taking care is hard work, and this journey would not be possible without you.
#Alzheimers
#demetia
$ANVS
1
1
13
$ANVS files a provisional patent covering manufacturing process for new solid forms of
#buntanetap
.
Learn more at
#Biotech
#Alzheimers
#Parkinsons
#Innovation
2
4
12
#DYK
that over 10 million people are living with
#ParkinsonsDisease
worldwide? At $ANVS, we are developing new treatment to help people suffering from PD. Our drug
#buntanetap
is currently in Phase 3.
Learn about our pipeline:
0
0
13
High levels of
#neurotoxic
proteins disrupt
#axonal
transport and lead to
#neurodegeneration
. At $ANVS, we believe that targeting these proteins simultaneously is the key to treating neurodegenerative diseases.
Read more
2
2
12
$ANVS will attend
#AAIC23
on July 16-20 in Amsterdam. Don’t miss the chance to see our poster presentations and meet our team.
More info at:
0
2
11